Day 1 : 23rd July 2022 | Saturday
Malaysian Time	Session Type	Speaker	Moderator/ Session Chair	Title of Presentation
11:20-11:40	Sponsored Symposium 1 - Roche	Dr Mastura Md Yusof		Reimagine Breast Cancer Care with Innovation Key Clinical Data of the Fixed Dose Combination of Pertuzumab and Trastuzumab for subcutaneous injection (PH FDC SC)
11:40-12:00	Sponsored Symposium 2 – (Illumina, Inc.)	Dr Chonglei, Bi		Enabling Next Level Comprehensive Genomic Profiling with Gold-Standard Homologous Recombination Deficiency (HRD) Insights
12:00 - 12:05	Welcome Address
12:05 - 13:10	Session 1 - Breast Local/ Regional/ Adjuvant/ Metastatic
12:05-12:15	Presentation	Dr Shazril Imran, Malaysia		LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0 luminal A breast cancer (BC).
12:15-12:25	Presentation	Dr Michael Gnant, USA		Long-term outcomes of adjuvant denosumab in breast cancer: Fracture reduction and survival results from 3,425 patients in the randomised, double-blind, placebo-controlled ABCSG-18 trial.
12:25-12:35	Presentation	Dr Rangasamy Ramachandran, Malaysia		Adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: 8-year follow-up of the randomized ASTRRA trial.
12:35-12:45	Presentation	Dr Daniel Gan, Malaysia		Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): results of DESTINY-Breast04 , a randomized, phase 3 study
12:45-12:55	Presentation	Dr Vaishnavi Jeyasingam, Malaysia		Primary Results From TROPiCS-02: A Randomized Phase 3 Study of Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC) in Patients (Pts) With Hormone Receptor-Positive/HER2-Negative (HR+/HER2-) Advanced Breast Cancer.
12:55-13:00	Quick Quiz Question
13:00-13:15	Exhibition Tour Break
13:15-13:35	Sponsored Symposium 3 - Zuillig Pharma	Dr Jennifer Leong Siew Mooi		Updates on CDK4/6 Inhibitors in the Management of HR+HER2- Metastatic Breast Cancer
13:35-14:05	Session 2 - Head & Neck
13:35-13:45	Presentation	Dr Aldrin Jasper Placidus, Malaysia		Refining nodal category in TNM staging with extent of extranodal extension for oral cavity squamous cell carcinoma.
13:45-13:55	Presentation	Dr Sangeeta Vahnalingam, Malaysia		Radiotherapy alone versus concurrent chemoradiotherapy in intermediate risk nasopharyngeal carcinoma: A multicentre, open-label, non-inferiority, andomized phase III trial.
13:55-14:05	Presentation	Dr Lee Hong, Malaysia		An open label non-inferiority phase III RCT of weekly versus three weekly cisplatin and radical radiotherapy in locally advanced head and neck squamous cell carcinoma (ConCERT trial).
14:05 - 14:25	Session 3 - Upper GI
14:05-14:15	Presentation	Dr Kumutha Chalaya, Malaysia		Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial.
14:15-14:25	Presentation	Dr Izzati Binti Wan Maharuddin, Malaysia		A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT as a predictive biomarker (ECOG-ACRIN E2211).
14:25 - 15:10	Session 4 - Lower GI
14:25-14:35	Presentation	Dr Jeanne Tie, Australia		Adjuvant chemotherapy guided by circulating tumor DNA analysis in stage II colon cancer: The randomized DYNAMIC Trial.
14:35-14:45	Presentation	Dr Sandya Subramaniam, Malaysia		Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): results from the phase 3 PARADIGM trial
14:45-14:55	Presentation	Dr Antonio Avallone, Italy		Improve Study: Randomized intermittent or continuous FOLFIRI/PANI for first-line treatment of patients (pts) with RASwt colorectal cancer
14:55-15:05	Presentation	Prof. Andrea Cercek, USA		Single agent PD-1 blockade as curative-intent treatment in mismatch repair deficient locally advanced rectal cancer.
15:05-15:10	Quick Quiz Question
15:10-15:30	Exhibition Tour Break
15:30-16:15	Sponsored Session 4 - BMS	Dr Elizabeth Smyth	Prof Ho Gwo Fuang	Transforming management of GI cancer with immuno-oncology
16:15-16:45	Session 5 - Gynaecology
16:15-16:25	Presentation	Dr Bradley Monk, USA		ATHENA-MONO: A randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib monotherapy as maintenance treatment following response to frontline platinum-based chemotherapy in ovarian cancer
16:25-16:35	Presentation	Dr Katherine The Hooi Lay, Malaysia		Mirvetuximab sorvatansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha: FRa expression: characterization of antitumor activity in the SORAYA study
16:35-16:45	Presentation	Dr Patricia Shamani Soosainathan, Malaysia		Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): the GARNET study
16:45-18:00	Session 6 - Genitourinary
16:45-16:55	Presentation	Dr Lim Chun Sen, Malaysia		EVEREST: EVErolimus for Renal cancer Ensuing Surgical Therapy, A phase III study
16:55-17:05	Presentation	Prof Adlinda Alip, Malaysia		Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Analysis of progression after first subsequent therapy in KEYNOTE-426.
17:05-17:15	Presentation	Dr Junie Khoo, Malaysia		The relationship between health-related quality of life (HRQoL) and clinical outcomes in patients with advanced renal cell carcinoma (aRCC) in CheckMate (CM) 214.
17:15-17:25	Presentation	Dr Faizah Binti Ab Muin, Malaysia		Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.
17:25-17:35	Presentation	Dr Vance Koi, Malaysia		Defining germline genetics of germ cell tumor: Implications for genetic testing and clinical management.
17:35-17:45	Presentation	Dr Michael Hofman, Australia		TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Overall survival aftermedian follow-up of 3 years (ANZUP 1603).
17:45-17:55	Presentation	Prof Marniza Saad, Malaysia		Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC).
17:55-18:00	Quick Quiz Question
END OF DAY 1
Day 2 : 24th July 2022 | Sunday
Malaysian Time	Session Type	Speaker	Moderator/ Session Chair	Title of Presentation
10:55-11:00	Day 2 Opening Remarks from Committee Member
11:00-11:50	Session 7 - Lung Cancer (NSCLC)
11:00-11:10	Presentation	Dr Ibtisam Binti Muhamad Nor		EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use.
11:10-11:20	Presentation	Dr Yusra Binti Hadi, Malaysia		Outcomes of anti-PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score ≥50%: FDA pooled analysis.
11:20-11:30	Presentation	Dr Norhidayu Salimin, Malaysia		Largest evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated non-small cell lung cancer (NSCLC) and colorectal cancer (CRC): Plasma biomarker analysis of CodeBreaK100.
11:30-11:40	Presentation	Dr Voon Pei Jye, Malaysia		KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation.
11:40-11:50	Presentation	Dr Karen Reckamp, USA		Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with immunotherapy: Lung-MAP non-matched sub-study S1800A.
11:50-12:25	Sponsored Symposium 5 - BMS	Prof Ravindran Kanesvaran	Dr Lim Chun Sen	Raising the bar for 2L RCC patients with Immunotherapy
12:25-13:00	Session 8 – Lung Cancer (Small Cell)
12:25-12:35	Presentation	Prof. Apar Kishor Ganti, USA		Comparison of quality of life in patients randomized to high-dose once daily (QD) thoracic radiotherapy (TRT) with standard twice daily (BID) TRT in limited stage small cell lung cancer (LS-SCLC) on CALGB 30610 (Alliance, Sub-study CALGB 70702).
12:35-12:45	Presentation	Prof. Charles Rudin, USA		SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC).
12:45-12:50	Quick Quiz Question
12:50-13:10	Exhibition Tour Break
13:10-13:30	Sponsored Session 6 - Astellas	Prof Ravindran Kanesvaran		Enzalutamide for the treatment of mHSPC : A closer look at the ARCHES and ENZAMET clinical studies
13:30-13:50	Session 9 – Musculoskeletal
13:30-13:40	Presentation	Dr Teh Kok Hoi, Malaysia		Phase III assessment of topotecan & cyclophosphamide and high-dose ifosfamide in rEECur, an international randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES).
13:40-13:50	Presentation	Dr Eng Jie Yi, Malaysia		Circulating tumor DNA (ctDNA) analyses of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor (GIST).
13:50-14:25	Session 10 – Central Nervous Tumour
13:50-14:00	Presentation	Dr Chan Min Jun, Malaysia		Prognostic validation and refinement of a classification system for extent of resection in glioblastoma: A report of the RANO resect group.
14:00-14:10	Presentation	Dr Kisha Subramaniam, Malaysia		Randomized phase II/III trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma (GBM) patients with MGMT promoter hypermethylation (Alliance A071102).
14:10-14:20	Presentation	Dr Audi Adawiah Sulaiman Shah, Malaysia		Phase II randomized study comparing proton craniospinal irradiation with photon involved-field radiotherapy for patients with solid tumor leptomeningeal metastasis.
14:20-14:25	Quick Quiz Question
14:25-14:55	Session 11 – Melanoma/ Skin Cancer
14:25-14:35	Presentation	Dr Teo Yin Keong, Malaysia		Distant metastasis-free survival with pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: the phase 3 KEYNOTE-716 study.
14:35-14:45	Presentation	Dr Tan Ai Lian, Malaysia		Neoadjuvant PD-1 blockade in patients with resectable desmoplastic melanoma (SWOG 1512).
14:45-14:55	Presentation	Dr Ooi Kai Yun, Malaysia		Nivolumab (NIVO) + relatlimab (RELA) versus NIVO in previously untreated metastatic or unresectable melanoma: OS and ORR by key subgroups from RELATIVITY-047
14:55-15:15	Exhibition Tour Break
15:15-15:35	Sponsored Symposium 7 – IPSEN	Dr Daniel Heng		Expanding Horizons - Optimizing frontline strategy in advanced RCC
15:35 -  16:10	Session 12 - Cancer Care & Regulatory policy/ Health Service Research & Quality Improvement
15:35-15:45	Presentation	Dr Noor Nabila Mohamad, Malaysia		Impact of broadening trial eligibility criteria on the inclusion of patients with brain metastases in cancer clinical trials.
15:45-15:55	Presentation	Dr Izzati Rosli, Malaysia		Evaluating mass implementation of digital health solutions to improve quality and reduce disparities in a large multisite community oncology practice.
15:55-16:05	Presentation	Dr.Vickee Rajeswaran, Malaysia		The PACES Study: A controlled before and after pragmatic trial of a cancer clinic based intervention to increase early referral to specialist palliative care.
16:05-16:10	Quick Quiz Question
16:00 onwards	Award Declaration & Valedictory